Evidence map›Paper›PMID 40878683›Full record

Trial reportStroke2025

Direct Endovascular Versus Bridging Therapy in M2 Segment Occlusion of Middle Cerebral Artery: A MR CLEAN Registry Study.

Mohamed F Doheim, Robrecht R M M Knapen, Julie Staals, Wouter J Schonewille, Diederik W J Dippel, Adriaan C G M van Es, Hester F Lingsma, Christiaan van der Leij, Charles B Majoie, Raul G Nogueira and 3 more

Abstract readMulticenter StudyRandomized Controlled TrialComparative Study
In one paragraph

Trial report in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mohamed F DoheimDepartment of Neurology, Stroke Institute, University of Pittsburgh Medical Center, PA (M.F.D., R.G.N.).ORCID 0000-0001-8279-5078
Robrecht R M M KnapenDepartments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.ORCID 0000-0003-4677-3685
Julie StaalsDepartment of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.ORCID 0000-0002-9502-6937
Wouter J SchonewilleDepartment of Neurology, St. Antonius Hospital, Nieuwegein, the Netherlands (W.J.S.).
Diederik W J DippelDepartments of Neurology (D.W.J.D.), Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-9234-3515
Adriaan C G M van EsDepartment of Radiology and Nuclear Medicine, Leiden University Medical Center, the Netherlands (A.C.G.M.v.E.).ORCID 0000-0002-4820-5051
Hester F LingsmaDepartments of Public Health (H.F.L.), Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-2063-9533
Christiaan van der LeijDepartments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.ORCID 0000-0003-0170-1012
Charles B MajoieDepartment of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (C.B.M.).ORCID 0000-0002-7600-9568
Raul G NogueiraDepartment of Neurology, Stroke Institute, University of Pittsburgh Medical Center, PA (M.F.D., R.G.N.).ORCID 0000-0003-4532-153X
Robert J van OostenbruggeDepartment of Neurology (R.R.M.M.K., J.S., R.J.v.O., M.F.D.), Maastricht University Medical Center+, the Netherlands.ORCID 0000-0003-1032-9099
Wim H van ZwamDepartments of Radiology and Nuclear Medicine (R.R.M.M.K., C.v.d.L., W.H.v.Z.), Maastricht University Medical Center+, the Netherlands.ORCID 0000-0003-1631-7056
MR CLEAN Registry Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal strategy for managing M2 segment occlusions of the middle cerebral artery, whether with direct endovascular treatment (EVT) or bridging therapy with intravenous thrombolysis (IVT) before EVT, remains unclear. This study aimed to evaluate the effectiveness and safety of both approaches.

methodsPatients with M2 segment occlusions of the middle cerebral artery, treated between March 2014 and December 2018, were identified from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), a prospective, nationwide, multicenter registry of patients with acute ischemic stroke who underwent endovascular treatment during that period. They were divided into 2 groups: those who received IVT followed by EVT, and those who received EVT alone. Primary outcomes included functional outcomes at 90 days, assessed by ordinal logistic regression analysis of modified Rankin Scale (mRS) scores. Secondary outcomes included recanalization rates measured by extended Thrombolysis in Cerebral Infarction scores, dichotomized mRS scores (0-1, 0-2, and 0-3), death at 90 days, and symptomatic intracranial hemorrhage. All analyses were performed using both unadjusted and adjusted multivariable approaches, with adjustment achieved through inverse probability of treatment weighting to account for baseline imbalances, including age, baseline National Institutes of Health Stroke Scale score, prior stroke, history of atrial fibrillation, anticoagulant use, and transfer status.

resultsA total of 539 patients with M2 occlusions were included in the analysis: 377 received IVT+EVT and 162 received EVT alone. The median age was significantly lower in the IVT+EVT group compared with the EVT-alone group (71 [61-79] versus 74 [65-81];

conclusionsBridging therapy may yield superior functional outcomes compared with EVT alone for patients with the middle cerebral artery-M2 occlusions.

Indexed as

Endovascular ProceduresInfarction, Middle Cerebral ArteryIschemic StrokeThrombolytic TherapyAgedAged, 80 and overFemaleFibrinolytic AgentsHumansMaleMiddle AgedProspective StudiesRegistriesTreatment OutcomeFibrinolytic Agentsintracranial hemorrhageischemic strokemiddle cerebral arterymortality

Identifiers

PMID40878683
PMCPMC12447822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.